Ara 290 vs MK-677
Extensively Studied vs Well Studied
synergistic Mechanism-based · 47% Ara 290 and MK-677 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ara 290 MK-677
Weight 1,257 Da 624.77 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) ~24 hours
Chain 11 amino acids —
Type Engineered peptide Non-peptide ghrelin receptor agonist
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Ara 290 MK-677
Status Extensively Studied Well Studied
References 5 studies 7 studies
Latest 2024 July 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.